

# An Evening with the Experts

## Myeloproliferative Neoplasms

Rami Komrokji, MD

# Diagnosis and risk stratification

- What is new in diagnostic criteria?
- What is the role of somatic mutation testing in MPN?
- How do we risk stratify patients?

# MF- Treatment updates

- When to consider allo- SCT?
- Where to use Ruxolitinib?
- How to define Ruxolitinib response and failure?
- Role of new approved Fedratinib?
- How to treat anemia/cytopenia in MF.
- What is on the horizon?
- Any role for interferon in MF?
- How to treat accelerated phase MPN?

# PV and ET treatment update

- When to start cytoreductive therapy?
- What is the goal of therapy in ET and PV?
- Do all patients above age 60 years need cytoreductive therapy?
- When to use Ruxolitinib in P. vera?
- What is the role of interferon in management of PV and ET